ArticleCancer control : journal of the Moffitt Cancer Center
Real-World Outcomes of Mantle Cell Lymphoma Treated With Rituximab-Based Chemotherapy Regimens: Experience From a Single Institution in Vietnam.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionThis single-center retrospective study aimed to assess the efficacy and safety of first-line rituximab-containing regimens in treatment-naïve patients with mantle cell lymphoma (MCL) in a resource-constrained setting.MethodsWe included 73 patients diagnosed with MCL between May 2019 and June 2024 who received rituximab-based chemotherapy (RB, RBAC, RDHAP, or RCHOP) at the Vietnam National Cancer Hospital. Clinical characteristics, treatment responses, survival outcomes, and prognostic factors were analyzed.ResultsThe median age was 60 years, and the male-to-female ratio was 2.17. Stage IV disease was present in 47.9% of patients and stage III in 38.4%. B symptoms were observed in 27.4%, and Ki-67 >30% in 45.2% of patients. The overall response rate (ORR) was 94.5%, including a complete response rate of 64.4%. The most common grade 3/4 adverse event was neutropenia (17.8%). The 3-year progression-free survival (PFS) and overall survival (OS) rates were 72.6% and 93.2%, respectively. Mantle Cell Lymphoma International Prognostic Index (MIPI) risk classification, treatment response, and extranodal involvement were associated with PFS, whereas OS was primarily influenced by treatment response.ConclusionRituximab-based chemotherapy appears to provide favorable efficacy and manageable toxicity in Vietnamese patients with MCL. These findings suggest that such regimens may remain a feasible first-line option in settings with limited access to novel agents and advanced supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.